SCHEMBL856042

SCHEMBL856042

N=CC(=O)N1CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27645872 0.80
SCHEMBL22731942 0.78
SCHEMBL29586735 0.76 CA2 (0.50)
SCHEMBL19629162 0.75 CA2 (0.38)
SCHEMBL1058394 0.75
SCHEMBL4660402 0.74 CA2 (0.58)
SCHEMBL1334849 0.72
SCHEMBL3613047 0.72
SCHEMBL1058395 0.70
SCHEMBL3403934 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642588-A2 Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease Chemokine Therapeutics Corporation (CA) 2006-04-05 EP claimed
US-20240218034-A1 MACROCYCLIC MODULATORS OF DISEASE ASSOCIATED PROTEIN MISFOLDING AND AGGREGATION RESQ BIOTECH (GR) 2024-07-04 US disclosed
US-11858974-B2 Macrocyclic modulators of disease associated protein misfolding and aggregation RESQ BIOTECH (GR) 2024-01-02 US disclosed
EP-4218784-A2 MACROCYCLIC MODULATORS OF DISEASE ASSOCIATED PROTEIN MISFOLDING AND AGGREGATION National Hellenic Research Foundation (GR) 2023-08-02 EP disclosed
US-20200140506-A1 MACROCYCLIC MODULATORS OF DISEASE ASSOCIATED PROTEIN MISFOLDING AND AGGREGATION NATIONAL HELLENIC RESEARCH FOUNDATION (GR) 2020-05-07 US disclosed
US-9290751-B2 LPL variant therapeutics Hayden, Michael R. (CA) 2016-03-22 US disclosed
US-20150030581-A1 LPL VARIANT THERAPEUTICS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-01-29 US disclosed
US-8268778-B2 Flavivirus NS5A proteins for the treatment of HIV UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2012-09-18 US disclosed
EP-2432497-A1 USE OF LIPOPROTEIN LIPASE (LPL) IN THERAPY Amsterdam Molecular Therapeutics (AMT) IP B.V. (NL) 2012-03-28 EP disclosed
US-20110269692-A1 ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF ALBANY MEDICAL COLLEGE 2011-11-03 US disclosed
EP-1200117-A2 LIPOPROTEIN LIPASE (LPL) VARIANT THERAPEUTICS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2002-05-02 EP disclosed
WO-2001090361-A2 MODULATION OF INFLAMMATION BY PROTEASE-TREATED MCP-3 CHEMOKINE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-29 WO disclosed
US-6319498-B1 AMYLOIDOGENIC PROTEIN, OR FRAGMENT THEREOF, MODIFIED WITH CIS-DECALIN GROUP, CHOLANOYL STRUCTURE, CHOLYL GROUP, DIETHYLENETRIAMINEPENTAACETYL GROUP, MENTHOXYACETYL GROUP, FLUORESCEIN-CONTAINING GROUP, OR N-ACETYLNEURAMINYL GROUP PRAECIS PHARMACEUTICALS INCORPORATED 2001-11-20 US disclosed
WO-2001085196-A2 CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001076615-A2 CXCR4 AGONIST TREATMENT OF HEMATOPOIETIC CELLS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-10-18 WO disclosed
US-6303567-B1 FOR DIAGNOSIS AND THERAPY OF AMYLOIDOGENIC DISEASES SUCH AS ALZHEIMER'S DISEASE PRAECIS PHARMACEUTICALS, INC . 2001-10-16 US disclosed
US-6277826-B1 CONSISTING OF D-LEUCINE, D-PHENYLALANINE AND D-VALINE; PEPTIDE IS MODIFIED AT THE AMINO-TERMINUS, THE CARBOXY-TERMINUS, OR BOTH WITH AN AMIDE OR A HYDROXY GROUP PRAECIS PHARMACEUTICALS, INC. 2001-08-21 US disclosed
WO-2001000220-A2 LIPOPROTEIN LIPASE (LPL) VARIANT THERAPEUTICS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-01-04 WO disclosed
US-5985242-A PEPTIDE OF 3 TO 5 D-AMINO ACIDS; MAY BE MODIFIED AT AMINO-AND/OR CARBOXY TERMINUS; FOR TREATMENT OF AMYLOIDOSIS, ALZHEIMER'S DISEASE PRAECIS PHARMACEUTICALS, INC. (US) 1999-11-16 US disclosed
US-5854204-A Aβ peptides that modulate β-amyloid aggregation PRAECIS PHARMACEUTICALS, INC. (US) 1998-12-29 US disclosed